期刊文献+

DAMPs对人肝癌HepG2细胞增殖能力影响的机制研究

Mechanism of the Effect of DAMPs on Human Hepatocellular Carcinoma HepG2 Cells
原文传递
导出
摘要 目的:探讨在损伤相关模式分子(DAMPs)诱导下人肝癌HepG2细胞增殖能力变化的发生机制。方法:将HepG2细胞分为对照组,DAMPs组,IL-6 siRNA组,IL-6 siRNA+DAMPs组;MTT比色法检测HepG2细胞增殖能力的变化;实时荧光定量PCR法检测IL-6及STAT3 mRNA的表达;Western blot法测定HepG2细胞STAT3蛋白和磷酸化STAT3蛋白的表达。结果:DAMPs组细胞增殖能力较对照组显著增强,IL-6 mRNA及STAT3 mRNA的表达较对照组显著上调,差异均有统计学意义(P<0.01);Western bot法检测出四组STAT3蛋白表达无明显差异,而DAMPs组磷酸化STAT3蛋白的表达高于对照组,差异有统计学意义(P<0.01)。结论:DAMPs可能通过IL-6/STAT3信号通路促进人肝癌HepG2细胞的增殖。 Objective: To investigate the mechanism of human hepatocellular carcinoma HepG2 cells pro- liferation induced by DAMPs. Methods: HepG2 cells were divided into four groups: control group, DAMPs group, IL-6 siRNA group, and IL-6 siRNA+DAMPs group. MTT assay was applied to investigate the proliferation of HepG2 cells. Expression of IL-6 and STAT3 mRNA in HepG2 cells was measured by quantitative RT-PCR, and the protein expression level of STAT3 and p-STAT3 was detected by Western blotting. Results: MTT assay demonstrated that the pro- liferation of HepG2 cells was enhanced when exposed to DAMPs (P〈0.01, vs. control). The result of quantitative RT-PCR showed that the expression of IL-6 mRNA and STAT3 mRNA in- creased markedly when exposed to DAMPs(P〈0.01, vs. control). The protein expression level of STAT3 among the four groups have no differences, but the p-STAT3 in DAMPs group werehigher than in control group (P〈0.01). Conclusion: DAMPs may promote the proliferation of HepG2 cell by IL-6/STAT3 signaling pathway.
出处 《武汉大学学报(医学版)》 CAS 北大核心 2013年第5期665-669,共5页 Medical Journal of Wuhan University
关键词 DAMPS IL-6 STAT3信号通路 HEPG2细胞 DAMPs IL-6/STAT3 Signaling Pathway HepG2 Cell
  • 相关文献

参考文献12

  • 1Hong DS,Angelo LS,Kurzrock R.Interleukin-6and its receptor in cancer:implications for translational therapeutics[J].Cancer,2007,110(9):1 911-1 928.
  • 2Berasain C,Castillo J,Perugorria MJ,et al.Inflammation and liver cancer new molecular links[J].Ann N Y Acad Sci,2009,1 155:206-221.
  • 3Kishimoto T.IL-6:from laboratory to bedside[J].Clin Rev Allergy Immunol,2005,28:177-186.
  • 4El-Serag HB,Rudolph KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132(7):2 557-2 576.
  • 5Balkwill F,Mantovani A.Inflammation and cancer:back to Virchow[J]?Lancet,2001,357(9 255):539-545.
  • 6Naugler WE,Sakurai T,Kim S,et al.Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production[J].Science,2007,317(5 834):121-124.
  • 7Xiang WQ,Feng WF,Ke W,et al.Hepatitis B virus X protein stimulates IL-6expression in hepatocytes via a MyD88-dependent pathway[J].J Hepatol,2011,54(1):26-33.
  • 8Yuan FJ,Zhang YS,Wei Y,et al.Increased expression of IL-6 mRNA in hepatocellular carcinoma cell lines correlates with biological characteristics[J].Asian Pacific J Cancer Prev,2011,12,3 361-3 365.
  • 9Kawai T,Akira S.TLR signaling[J].Seminars in Immunology,2007,19:24-32.
  • 10Matzinger P.Friendly and dangerous signals:is the tissue in control[J]?Nat Immuno,2007,8:11-13.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部